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A B S T R A C T
The HLA class II histocompatibility antigen gamma chain, also known as HLA-DR antigen-associated invariant
chain or CD74, has been shown to be involved in many biological processes amongst which antigen loading and
transport of MHC class II molecules from the endoplasmic reticulum to the Golgi complex. It is also part of a
receptor complex for macrophage migration inhibitory factor (MIF), and participates in inﬂammatory signaling.
The inhibition of MIF-CD74 complex formation is regarded as a potentially attractive therapeutic target in
inﬂammation, cancer and immune diseases. In order to be able to produce large quantities of the extracellular
moiety of human CD74, which has been reported to be unstable and protease-sensitive, diﬀerent constructs were
made as fusions with two solubility enhancers: the well-known maltose-binding domain and Fh8, a small protein
secreted by the parasite Fasciola hepatica. The fusion proteins could be puriﬁed with high yields from Escherichia
coli and were demonstrated to be active in binding to MIF. Moreover, our results strongly suggest that the MIF
binding site is located in the sequence between the transmembrane and the membrane-distal trimerisation
domain of CD74, and comprises at least amino acids 113–125 of CD74.
1. Introduction
CD74 (Cluster of Diﬀerentiation 74), also referred to as HLA class II
histocompatibility antigen gamma chain or HLA-DR antigen-associated
invariant chain Ii, is a non-polymorphic type II transmembrane glyco-
protein that has been demonstrated to perform a variety of cellular
functions. It was initially identiﬁed in complex with major histo-
compatibility complex class II (MHCII) molecules and soon recognized
for its role in antigen presentation via its involvement in assembly and
subcellular traﬃcking of the MHCII complex [1]. The four isoforms of
human CD74 diﬀer in activity and cellular expression [2,3]. Due to an
arginine motif in their N-terminal extension, isoforms p35 and p43 are
retained in the endoplasmic reticulum (ER) except when they form a
complex with MHCII molecules, in which this retention motif is masked
so that the complex can traﬃc to post-ER compartments. Typically, the
luminal domain of CD74 undergoes progressive proteolytic degradation
in the endosomal/lysosomal system, ﬁnally leaving a fragment, the
small class-II-associated invariant chain peptide (CLIP), attached to the
MHC class II molecule. In contrast to p35 and p45, isoforms p33 and
p41 do not have the ER retention signal allowing these isoforms to
traﬃc in non-MHCII expressing cells [3].
In addition to its role in subcellular traﬃcking, a small portion of
CD74 functions as a cellular receptor for the immune regulatory cyto-
kine macrophage migration inhibitory factor (MIF). Although MIF can
also bind to G-protein coupled receptors CXCR2, CXCR4 and CXCR7,
the CD74-mediated signaling is recognized to play an important role in
many diseases connected to inﬂammation, as well as cell proliferation
and diﬀerentiation [4–6]. Recently, serum levels of not only MIF but
also the soluble, circulating version of CD74 were reported to be related
to liver and respiratory diseases [7,8]. Taken together, the MIF-CD74
interaction and the related signaling pathway have become attractive
targets for novel therapies, as also illustrated by the humanized
monoclonal anti-CD74 antibody milatuzumab that recently received
orphan drug designation from the Food and Drug Administration in the
USA for the treatment of multiple myeloma and chronic lymphocytic
leukemia [9]. Excellent descriptions of the biological and structural
aspects of CD74 can be found in two recent reviews [2,10].
In the light of CD74's fate in the endosomal/lysosomal system, it
may not be surprising that the study of the binding of MIF to CD74 is
hampered by the partially unstable structure of CD74; only the
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trimerisation domain within the extracellular moiety appears to have a
stable structure [11]. In addition, the production yield of the extra-
cellular moiety of CD74 in bacterial cells is not very high [12]. The
application of fusion technology via the use of aﬃnity fusion tags, in
particular solubility enhancing peptides, is frequently used to improve
the yield of active, pure protein [13–15]. We have tested two aﬃnity
tags: the well-documented maltose-binding protein (MBP) and the re-
cently reported small EF-hand protein Fh8 from the parasitic trematode
Fasciola hepatica. MBP is a large (43 kDa), highly soluble protein of E.
coli that acts as a solubility enhancer tag [16]. For puriﬁcation, MBP
fusion proteins can bind to immobilized amylose resins and be eluted
using maltose [17]. Similar to MBP, the small (8 kDa) protein Fh8
combines solubility enhancing properties to the possibility of aﬃnity
chromatography [18–20].
In this study we made use of the MBP and Fh8 fusion partners to
obtain a high yield of soluble CD74 and characterized the puriﬁed fu-
sion proteins for binding to MIF. In addition to the fused proteins, we
also tested the cleaved products for their binding activity. The results
allowed us to conclude that the extracellular moiety of CD74 between
the transmembrane region and the membrane-distal trimerisation do-
main, in particular amino acids 113–125, is involved in binding of MIF.
2. Materials and methods
Procedures for restriction enzyme digestions, ligation, transforma-
tion, and other standard molecular biology manipulations were per-
formed as described by Sambrook et al. [21]. The PCR was carried out
in a DNA thermal cycler model GS-1 (Biolegio, The Netherlands). DNA
sequencing was performed by Macrogen, Korea. Proteins were analyzed
by gel electrophoresis using 10% sodium dodecyl sulphate poly-
acrylamide gels (SDS-PAGE; Invitrogen, The Netherlands). The gels
were stained with InstantBlue protein stain (Expedeon, UK). Protein
markers used for SDS-PAGE were PageRuler Prestained Protein Ladder
marker (Thermo Scientiﬁc, The Netherlands) or SeeBlue Plus2 Pre-
stained marker (Invitrogen, The Netherlands).
Protein concentrations were determined by the Pierce™ Coomassie
Protein Assay (ThermoFischer Scientiﬁc, The Netherlands) using bovine
serum albumin as a reference. Molar concentrations of MIF and CD74
proteins refer to the concentrations of their subunits.
Molecular weight analysis of puriﬁed proteins or proteins extracted
from SDS-PAGE gels were performed by electrospray ionization-mass
spectrometry using a Sciex API 3000 triple quadrupole mass spectro-
meter (AB Sciex, Canada), housed in the Mass Spectrometry Facility at
the University of Groningen.
2.1. Plasmids and bacterial strains
The plasmid and bacterial strain used for MIF production in this
study was pET20b(+) (Addgene, UK) and E. coli BL21 (DE3), respec-
tively [22]. The plasmid and bacterial strains used for CD74 production
were pET20b(+) and Rosetta-gami 2(DE3) (Novagen, Germany) for the
MBP fusion proteins; and pET14b (Addgene, UK) and E. coli BL21 star
(DE3) pRARE2 (Thermo Fisher Scientiﬁc, The Netherlands) for the Fh8
fusion proteins.
2.2. DNA manipulations
2.2.1. Construction of pET20b-MBP-sCD74 expression vector
Plasmid pCR T7/CT TOPO encoding the extracellular domain of
human CD74 with a C-terminal His-tag was a kind gift from Prof.
Richard Bucala [4].
The MBP-sCD74 fusion construct was generated by the overlap ex-
tension PCR method. The ﬁrst DNA fragment, containing the MBP gene
and the sequence encoding the factor Xa cleavage site, was ampliﬁed by
PCR using pMAL-c2X vector as a template and a pair of primers: MBP-
EXT-Fw (5′-CAG CGA CAT ATG AAA ATC GAA GAA GGT AAA CTG
GTA ATC-3’; NdeI site in bold) and MBP-FUS-Rv (5′-ACG ACC TTC GAT
GAA TTC TGA AAT CCT TCC CTC GAT CCC GAG GTT-3’; nucleotide
sequence encoding the factor Xa cleavage site is underlined). The
second fragment, containing the sCD74 gene was ampliﬁed using
pET20b (sCD74) as a template. Plasmid pET20b-sCD74 was made as
follows: the CD74 gene was ampliﬁed (primers: CD74-Fw: 5′-CAG CGA
CAT ATG CAG GGC CGG CTG GAC AAA CTG ACA GTC ACC-3′, NdeI
site in bold; and CD74-Rv: 5′-CTG ATG GAT CTC GAG CAT GGG GAC
TGG GCC CAG ATC CTG CTT-3′, XhoI site in bold) and, after NdeI/XhoI-
digestion, ligated into the pET20b vector. The sCD74 gene fragment
was ampliﬁed from this plasmid using the following primers: MBP-FUS-
Fw (5′-AAC CTC GGG ATC GAG GGA AGG ATT TCA GAA TTC ATC GAA
GGT CGT CAG GGC CGG CTG GAC AAA CTG ACA GTC ACC TC-3’;
nucleotide sequences for factor Xa cleavage site underlined) and CD74-
Rv. The two fragments generated in the ﬁrst round of PCR were fused in
the second round using MBP-EXT-Fw and CD74-Rv primers. After di-
gestion with NdeI and XhoI and puriﬁcation, this fragment was ligated
into the pET20b vector cleaved with the same restriction enzymes. The
newly constructed expression vector was denoted pET20b-MBP-sCD74
and its ﬁdelity was conﬁrmed by DNA sequencing.
2.2.2. Construction of pCoBo-Fh8-sCD74 and pCoBo-Fh8-ssCD74
expression vectors
For production of Fh8-fused proteins, a modiﬁed pET15b vector was
created that contains two multiple cloning sites separated by a 3C
cleavage sequence in the following manner: (1) The HindIII site in
pET15b was removed by mutagenesis; (2) oligonucleotides were de-
signed with restriction sites AgeI and KpnI followed by a DNA stretch
encoding the rhinovirus 3C proteolytic site (LEVLFQ/GP) and with a
NcoI sequence on each end of the oligonucleotides, allowing cloning
into the NcoI site of pET15b. The oligos were designed in such a manner
that the “upstream” NcoI site closest to the T7 promotor would be lost.
The proper orientation of this insert in the modiﬁed plasmid was
checked by restriction analysis and sequencing; (3) The DNA encoding
Fh8 was ampliﬁed from plasmid pD454-Fh8 (DNA2.0 Inc., U.S.A.) using
the following primers carrying AgeI and KpnI restriction sites (in bold),
respectively: Fh8AQUAFwd (5′-TTA AGA AGG AGA TAT ACC ATG CAA
ACC GGT ATG CCG AGC GTT CAA GAA G-3′) and Fh8AQUARev (5′-
TTG AAA AAG CAC TTC AAG ACC TCC GGT ACC AGA TGT GCC GCT
GCT CAG-3′). The DNA fragment was cloned into the modiﬁed pET15b
vector cleaved with AgeI and KpnI using AQUA cloning [23]; (4) Oli-
gonucleotides were designed to insert a new multiple cloning site
comprising restriction sites BamHI, HindIII, NdeI, SmLI, XhoI, SmaI,
XmaI, with an upstream NcoI site and a dysfunctional BamHI site
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downstream. The hybridised oligos were ligated in the plasmid cleaved
with NcoI and BamHI. This plasmid was named pCoBo-Fh8.
The CD74 gene on the pET20b-MBP-sCD74 plasmid was ampliﬁed
using the following primers: CD74-Fwd (5′-GCA TCA GGA TCC ATT
GGA GCA AAT AAG CTT CGG CTG GAC AAA CTG AC-3′) and CD74-
Rev (5′-TTG TTA GCA GCC GGA TCG TCA TTA CCC GGG GG ATC TCA
GTG GTG GTG-3′) for Fh8-sCD74; and CD74-Fwd (5′-GCA TCA GGA
TCC ATT GGA GCA AAT AAG CTT CTG CTG ATG CAG GCG-3′) and
CD74-Rev (5′-TTG TTA GCA GCC GGA TCG TCA TTA CCC GGG GG
ATC TCA GTG GTG GTG-3′) for Fh8-ssCD74, carrying HindIII and SmaI
restriction sites (bold). After digestion, the DNA fragment was ligated
into the pCoBo-Fh8 vector cleaved with HindIII and SmaI, resulting in
pCoBo-Fh8-sCD74 and pCoBo-Fh8-ssCD74, respectively. The inserts of
all constructs were checked by DNA sequencing.
2.3. Protein production and puriﬁcation
2.3.1. Production and puriﬁcation of CD74 fusion proteins
The pET20b-MBP-sCD74 and pCoBo-Fh8-sCD74 were transformed
into Rossetta-gami 2 (DE3) and BL21 Star (DE3) +pRARE2 strain, re-
spectively. For protein production, overnight pre-cultures were used to
inoculate 1 L 2 YT medium in a 5 L Erlenmeyer ﬂask. Cultures were
then grown until OD600 ∼ 0.5. Isopropyl β-thiogalactopyranoside was
added to a ﬁnal concentration of 50 μM and the cultures were incubated
overnight at 20 °C. Cells were harvested by centrifugation (3500× g,
15min, 4 °C), washed with 0.9% NaCl and the cell pellet stored at
−20 °C until further use. In a typical puriﬁcation experiment, 10 g cell
pellets from a 1 L culture were thawed and suspended in 15mL of lysis
buﬀer (50mM Tris-HCl, 10% glycerol, pH 7.4) supplemented with 1
tablet protease inhibitor (Roche, The Netherlands), 19mg EDTA and
19mg EGTA. Cells were disrupted by sonication for 6×30 s while
cooled in ice-water (with 90 s rest in between each cycle) at a 50% duty
cycle and 240W output using a Branson soniﬁer model 450 (Branson
Ultrasonics Corporation, U.S.A.), after which cell debris was removed
by centrifugation (34,000× g, 60min, 4 °C). The cell free extract (su-
pernatant) was incubated overnight at 4 °C with 5mL cOmplete HisTrap
puriﬁcation resin (Roche Life Science, The Netherlands), pre-equili-
brated with lysis buﬀer. The non-bound proteins were removed as ﬂow
through by gravity ﬂow. The column was then washed with 50mL lysis
buﬀer followed by 12mL HT elution buﬀer (50mM Tris-HCl, 500mM
imidazole, 10% glycerol, pH 7.4). Fractions were analyzed by SDS
PAGE and those containing CD74 fusion proteins pooled.
HisTrap-puriﬁed MBP-fused CD74 proteins were applied to a gravity
column containing 5mL MBPTrap resin, pre-equilibrated with MT
buﬀer (50mM Tris-HCl, 10% glycerol, pH 7.4). After an overnight in-
cubation at 4 °C while mixing on a rotor, the non-bound proteins were
removed from the column with 50mL of MT buﬀer. Bound protein was
eluted with 3.5mLMT elution buﬀer (50mM Tris-HCl, 10 mM maltose,
10% glycerol, pH 7.4). Fractions were analyzed by SDS PAGE, those
containing CD74 fusion proteins were pooled, aliquoted, snapfrozen
and stored in aliquots at −80 °C.
Fh8-fused CD74 proteins could be further puriﬁed by a 5mL octyl
sepharose column (GE Healthcare, The Netherlands) at 10 °C as de-
scribed [12]. In short, the protein was dialysed against OS buﬀer
(50mM Tris-HCl, 150mM NaCl, 5 mM CaCl2, 10% glycerol, pH 7.6)
and loaded on a 5-mL octyl sepharose column (GE Healthcare, The
Netherlands), pre-equilibrated with OS buﬀer. After washing with low
CaCl2-buﬀer (25mM Tris-HCl, 75 mM NaCl, 2.5mM CaCl2, 10% gly-
cerol, pH 7.6), the protein was eluted with 50mM Tris, 5 mM EDTA,
10% glycerol, pH 7.6. Fractions were analyzed by SDS PAGE, those
containing Fh8-fusion proteins were pooled, aliquoted, snapfrozen and
stored in aliquots at −80 °C.
2.3.2. Factor Xa cleavage of MBP-sCD74
The cleavage of the MBP-sCD74 fusion protein was performed in
50mM Tris-HCl, 10% glycerol supplemented with 50mM NaCl and
2mM CaCl2 at pH 7.4 by factor Xa protease (NEB, The Netherlands)
with a mass/volume (μg/μL) ratio MBP-sCD74:factor Xa of 25:1, 3 h
incubation period at 4 °C. The cleaved product was puriﬁed using
cOmplete His-Trap puriﬁcation resin. Fractions were analyzed by SDS
PAGE, those containing sCD74 were pooled, aliquoted, snapfrozen and
stored in aliquots at −80 °C.
2.3.3. 3C cleavage of Fh8-ssCD74
The cleavage of the Fh8-ssCD74 fusion protein was performed in
50mM Tris-HCl, 10% glycerol supplemented with 150mM NaCl at pH
7.4 by 3C PreScission protease (GE Healthcare, The Netherlands) with a
mass/volume (μg/μL) ratio Fh8-ssCD74:3C of 100:1, 1 h at 4 °C. The
cleaved product was puriﬁed using octyl sepharose resin (GE
Healthcare, The Netherlands) followed by cOmplete His-Trap pur-
iﬁcation resin, as described above. Fractions were analyzed by SDS
PAGE, those containing ssCD74 were pooled, aliquoted, snapfrozen and
stored in aliquots at −80 °C. Protein sssCD74, produced by overnight
incubation of Fh8-ssCD74 with 3C Precission protease at 4 °C, was
puriﬁed using cOmplete HisTrap resin.
2.3.4. Peptides MBP and Fh8
MBP was purchased from ProSpec-Tany TechnoGene Ltd
(Germany). Fh8 was produced with pCoBo-Fh8 and puriﬁed using octyl
sepharose resin.
2.3.5. Production and puriﬁcation of MIF
MIF was produced in BL21(DE3) in a similar manner as MBP-sCD74.
After harvesting, cells were resuspended in lysis buﬀer supplemented
with 1 tablet protease inhibitor (Roche, The Netherlands). Cell free
extract was obtained as described earlier for MBP-sCD74 and incubated
overnight at 4 °C with 5mL cOmplete His-Trap puriﬁcation resin
(Roche, The Netherlands), which had previously been equilibrated with
the lysis buﬀer. The non-bound proteins were removed as ﬂow through
by gravity ﬂow. The column was washed with 50mL lysis buﬀer fol-
lowed by 12mL elution buﬀer (50mM Tris-HCl, 500mM imidazole,
10% glycerol, pH 7.4). Fractions were analyzed by SDS PAGE and those
containing MIF were pooled, aliquoted, snap-frozen and stored at
−80 °C.
2.4. Analysis of proteins using size exclusion chromatography
MIF and CD74 proteins were analyzed separately on an analytical
size exclusion column. 20 μL of a 1mg/mL protein solution was injected
and run at 0.2mL/min on a 3ml Superdex200 5/150 column (GE
Healthcare), equilibrated with PBS, pH 7.4, at 10 °C. To calibrate the
column, the elution volumes of ﬁve marker proteins (GE Healthcare)
were determined under identical conditions: thyroglobulin (669 kDa),
ferritin (440 kDa), aldolase (158 kDa), conalbumin (75 kDa), and
ovalbumin (43 kDa).
2.5. Binding assays
2.5.1. Enzyme-linked immunosorbent assay (ELISA)
The sCD74 proteins were characterised for MIF binding in an ELISA
test. Wells in 96-well plates were coated with 100 μL of 300 nM MIF in
phosphate-buﬀered saline (PBS) [400 ng/well]. After washing with
200 μL buﬀer PBS + Tween 0.05% and blocking with commercial
blocker (Rockland, The Netherlands), 100 μL of 500 nM sCD74 was
added, and the system was incubated for 30 min at room temperature.
After the wells were washed and blocked, mouse anti-MBP mAb
(SigmaAldrich, The Netherlands) or rabbit anti-CD74 pAb
(Sinobiological, The Netherlands) was added. The bound complexes
were detected after washing by the addition of goat anti-mouse
horseradish peroxidase conjugate (Thermo Fisher Scientiﬁc, The
Netherlands) or goat anti-rabbit horseradish peroxidase conjugate (Life
Technologies, The Netherlands), and tetra methylbenzydine (Thermo
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Fisher Scientiﬁc, The Netherlands) as its substrate. After ∼10 min the
reaction was stopped by the addition of 1M H2SO4 and the absorbance
at 450 nm measured. The speciﬁcity of binding was conﬁrmed by using
100 μL of 500 nM MBP in PBS, and 100 μL of 500 nM Fh8 in PBS as
controls. Each experiment was done in triplicate and repeated at least
two times.
A dose-dependent ELISA was performed with sCD74 concentration
ranging from 3 to 3200 nM (for MBP-sCD74) and 12–3200 nM (for Fh8-
ssCD74). The corrected absorbance at 450 nm was then plotted against
logarithm of concentration to determine the dissociation constant
2.5.2. Isothermal Titration Calorimetry (ITC)
Binding of MIF to CD74 was measured by ITC model ITC200
(Malvern, UK) at 25 °C, 1000 rpm stirring speed, 120 s spacing between
each injection. The cell was ﬁlled with 200 μL of 40–85 μM MBP-sCD74
in PBS and titrated with 20 consecutive injections of 2 μL 70–220 μM
MIF in PBS. A cell ﬁlled with PBS only titrated with MIF and a cell ﬁlled
with fusion protein titrated with PBS only were used as control.
3. Results and discussion
Even though MIF was one of the ﬁrst cytokines to have been de-
scribed, many details of its signaling activities still have to be eluci-
dated. Nevertheless, the involvement of receptor CD74 has been proven
in many MIF-related diseases and this receptor has been recognized as a
major pharmaceutical target. The interaction between MIF and CD74
was in vitro demonstrated to be located in the extracellular moiety of
CD74 [4,24]. However, the unstable and protease-prone character of
the extracellular moiety of CD74 has hampered further characterisa-
tion. Several attempts to obtain a good production of the extracellular
moiety of CD74 with a C-terminal His-tag in bacteria resulted in low
yields of soluble protein [12]. As a consequence, we have tried to tackle
this problem by fusing CD74 to solubility-enhancing peptides. Two
diﬀerent solubility enhancing peptides were used: the large, but well
characterised MBP protein [14] and the recently reported small protein
Fh8 [18]. Fig. 1 presents a schematic overview of the fusion proteins
encoded by the constructs that were made, and their corresponding
Fig. 1. (A) Schematic presentation of human CD74 isoform p35 and CD74 proteins used in this study. IC= intracellular (residues 1–46), TM= transmembrane
(residues 47–73), EC= extracellular (residues 74–232), the inverted triangles indicate where isoforms p33, p35, p41 and p43 diﬀer. Xa= factor Xa cleavage site,
3C= 3C protease cleavage site, His6 = (His)6-tag. (B) Amino acid sequences of CD74 proteins used in this study. The sequences of the solubility enhancing
peptides MBP and Fh8 are in italics, the proteolytic sites are underlined, and the CD74 sequences are presented in bold. Sequences of CD74 that are dotted or dashed
underlined represent the CLIP region and the membrane-distal trimerisation domain, respectively.
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amino acid sequences.
3.1. Production and puriﬁcation of CD74 proteins
The fragments of the human CD74 gene as cloned into the expres-
sion vectors were not codon-optimized for bacterial expression.
Therefore, we used E. coli strains that were transformed with the
plasmid pRARE2 supplying tRNAs for 7 rare codons (AGA, AGG, AUA,
CUA, GGA, CCC, and CGG), e.g. the strains Rossetta-gami 2 (DE3) and
BL21 Star (DE3) + pRARE2. This allowed high production yields of
soluble MBP-sCD74, Fh8-sCD74 and Fh8-ssCD74 (Fig. 2).
Fusion protein MBP-sCD74 was successfully puriﬁed by aﬃnity
chromatography using a HisTrap column followed by a MBP-Trap
column. Mass spectrometric analysis of the major band running just
below the 62 kDa marker protein (Fig. 3, lane 3) gave a mass of
62.326 kDa which corresponds to the calculated MW of 62.319 kDa. MS
analysis of the tryptic digestion of the protein conﬁrmed the identity of
MBP-sCD74 by>90% coverage. About 60mg of puriﬁed MBP-sCD74
was obtained from 1 L of culture. Mass analysis of a contaminating
protein running above the 14 kDa marker protein (Fig. 3, lane 3)
showed this to be a 14.711 kDa peptide, corresponding to a degradation
product with a proteolytic cleavage between residues Pro112 and
Leu113 of CD74. This deviates from previously observed cleavage sites
in this region [25,26], a diﬀerence that is likely to be related to dif-
ferences in E. coli strains and growth conditions that were used, and/or
to the N- or C-terminally located His-tag leading to puriﬁcation of dif-
ferent fragments. The proteolytic sensitivity is supported by the NMR
study of fragment 133–208 of CD74, which showed that amino acids
directly ﬂanking the trimerisation domain are disordered [27]. In line
with this, the CLIP region (residues 97–119) appears as a linear peptide
without secondary structure in complex with MHCII molecules
[28–31].
The large size of MBP (42 kDa) made us decide to also construct a
fusion of sCD74 with the much smaller Fh8 protein, an EF-hand protein
of 8 kDa that shows calcium-dependent binding to hydrophobic resins.
The Fh8-sCD74 fusion protein was ﬁrst puriﬁed by aﬃnity chromato-
graphy on a HisTrap column. Similar to MBP-sCD74, puriﬁcation of
Fh8-sCD74 on the cOmplete HisTrap column resulted in an approxi-
mately 90% pure protein with an experimentally determined mass of
29.604 kDa, corresponding to the calculated mass of 29.605 kDa. The
yield of Fh8-sCD74 was 30mg per liter culture. Mass analysis of the
contaminant protein running above the 14 kDa marker protein in the
SDS-PAGE gel (Fig. 3, lane 2) demonstrated this protein to have a mass
of 14.711 kDa, similar to the contamination found in the MBP-sCD74
protein batch. Unfortunately, the octyl sepharose column did not im-
prove the purity of the fusion protein. The diﬃculty to remove de-
gradation products from fusion products are most likely due to the
multimeric character of CD74: cleavage in loop regions does not ne-
cessarily aﬀect trimer formation of CD74-derived proteins nor their
chromatographic behaviour.
In an attempt to create a more protease-stable fragment of sCD74, a
plasmid encoding fusion protein Fh8-ssCD74 (CD74 residues 113–232)
was constructed (Fig. 1). Production of this protein and puriﬁcation on
a cOmplete HisTrap column (Fig. 3, lane 1) resulted in the high yield of
75mg of∼95% pure protein per liter of culture with an experimentally
determined mass of 25.461 kDa, corresponding to the calculated mass
of 25.462 kDa. As anticipated, the previously observed contaminant of
14.711 kDa was not found in this protein batch.
In order to obtain the non-fused sCD74, fusion protein MBP-sCD74
was cleaved with factor Xa, followed by puriﬁcation on a HisTrap
column. This resulted in a mixture of sCD74 and lower molecular
weight products (Fig. 3, lane 5). Apparently, the MBP-sCD74 fusion
protein is prone to cleavage with factor Xa at additional sites. Attempts
to improve the purity of sCD74 by size exclusion and ion exchange
chromatography were unsuccessful.
Similarly, 3C-mediated cleavage of Fh8-ssCD74 and subsequent
puriﬁcation of ssCD74 also resulted in a mixture of proteins of slightly
smaller mass (results not shown). Also here, chromatography attempts
Fig. 2. Overproduction of CD74 fusion proteins. Lane 1: marker proteins
with the indicated molecular weights. Lanes 2 and 3: cell lysate before and after
overproduction of Fh8-ssCD74 (MW 25.0 kDa), respectively. Lanes 4 and 5: cell
lysate before and after overproduction of Fh8-sCD74 (MW 29.6 kDa), respec-
tively. Lanes 6 and 7: cell lysate before and after overproduction of MBP-sCD74
(MW 62.3 kDa), respectively.
Fig. 3. SDS gel of diﬀerent puriﬁed CD74 proteins. Fh8-ssCD74 (lane 1),
Fh8-sCD74 (lane 2), MBP-sCD74 (lane 3), sCD74 (lane 5), and sssCD74 (lane 6).
Lane 4 contains the protein marker with indication of their molecular weights.
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to recover ssCD74 using HisTrap as a highly puriﬁed protein were not
successful. Further experimentation indicated that a stable cleavage
product of ssCD74, denoted as sssCD74, was obtained after overnight
incubation at 4 °C with 3C protease. Mass spectrometry analysis de-
monstrated that the molecular weight of this product was 13.343 kDa,
corresponding to residues 126–232 with C-terminal His-tag, thus
lacking almost the whole region up to the membrane-distal trimerisa-
tion domain of CD74 (Fig. 1). This fragment could be highly puriﬁed
with a cOmplete HisTrap column (Fig. 3, lane 6). Noteworthy, fragment
sssCD74 is comparable to the 18 kDa proteolytic fragment K3, that re-
tains the ability to bind to MHCII molecules, and, like sssCD74, starts at
residue Gly126 but has a C-terminal truncation [32].
When analyzed on an analytical size exclusion column, the fusion
proteins MBP-sCD74, Fh8-sCD74 and Fh8-ssCD74 eluted earlier than
expected (Fig. 4). Although expected to run as trimers with molecular
weights 186.9, 88.8, and 77.5 kDa, respectively, they eluted between
the reference proteins ferritin (MW 440 kDa) and aldolase (158 kDa). At
ﬁrst impression, this seems to indicate that the fusion proteins form
hexameric instead of trimeric structures. However, since fusion partners
MBP and Fh8 are considered to be stable monomers, and since the
elution volumes of cleaved products sCD74 and sssCD74 correspond to
the expected elution volumes of their trimeric versions (60.9 and
39.9 kDa, respectively), this behaviour is more likely to be a con-
sequence of increased hydrodynamic shapes of the trimeric fusion
proteins. Such behaviour is not unexpected for fusion proteins that
consist of two well-deﬁned domains separated by an intrinsically dis-
ordered moiety. Our results suggest that all CD74 proteins used in this
study are mostly present in a homotrimeric form. However, the chro-
matograms of the three fusion proteins show more than one peak in-
dicating some heterogeneity. Fh8-sCD74 shows two major peaks which
are not easily explained. MBP-sCD74 and Fh8-sCD74 show a small peak
at c. 40 kDa, which can be interpreted as the trimer of the 14.711 kDa
contamination.
As expected, the elution volume of MIF ﬁts to its trimeric form
(40.3 kDa; Fig. 4).
3.2. MIF binding capacities of CD74 proteins
The MIF binding capacities of the diﬀerent CD74 proteins were
assessed by ELISA. As depicted in Fig. 5A and B, all fusion proteins of
CD74 were able to bind to this cytokine. The lack of MIF binding to the
MBP and Fh8 polypeptides demonstrated that the interactions of the
CD74 fusion proteins with MIF are a consequence of the presence of
CD74 and not of the fusion partners. Interestingly, at a concentration of
500 nM, fusion protein Fh8-ssCD74 gave a lower MIF-binding response
than Fh8-sCD74 (Fig. 5B) indicating that deletion of residues 77–112 of
CD74 only partially aﬀects the binding to MIF. The binding capacity of
500 nM non-fused sCD74 itself is also shown in Fig. 5C. Deletion of
residues 77–125 in the luminal moiety up to the membrane-distal tri-
merisation domain resulted in a strong loss of MIF binding capacity as is
demonstrated by the lack of binding of 500 nM puriﬁed protein sssCD74
(Fig. 5C). This is not due to a loss of structural stability since both
sCD74 and sssCD74 behave as trimeric proteins during size exclusion
chromatography (Fig. 4). These results thus strongly suggest that the
MIF-binding region lies N-terminal to the membrane-distal trimerisa-
tion domain of CD74.
These biochemical results diﬀer from the results of a docking ex-
periment in which amino acid sequences YGNMT and RHSLE within the
trimerisation domain were predicted to be involved in the binding to
MIF [33]. The docking experiment – as it is depending on three-di-
mensional structures - was performed with the structures of MIF (PDB
Fig. 4. Size exclusion chromatography of MIF and sCD74 proteins on a
Superdex200 5/150 column (GE Healthcare, The Netherlands). Puriﬁed pro-
teins were separately analyzed on a 3mL gel ﬁltration column Superdex200 5/
150 by injecting 20 μl of a 1mg/ml protein solution onto the column equili-
brated with PBS, pH 7.4, at 10 °C. Each chromatogram was normalised to its
absorbance at 280 nm. The column was also calibrated with 20 μl of 1 mg/ml
solutions of ﬁve marker proteins: thyroglobulin (669 kDa), ferritin (440 kDa),
aldolase (158 kDa), conalbumin (73 kDa), and ovalbumin (43 kDa). The elution
volumes of these marker proteins (1.19; 1.34; 1.61; 1.78; and 1.89ml, resp.) are
indicated with arrows.
Fig. 5. ELISA binding observation between MIF
and sCD74 fusion proteins. (A) MIF with 500 nM
MBP-sCD74 and controls using mouse anti-MBP
mAb for detection (B) MIF with 500 nM MBP-
sCD74, Fh8-sCD74 or Fh8-ssCD74 and controls
using rabbit anti-CD74 pAb for detection. (C) MIF
with 500 nM sCD74 or sssCD74 and controls
using rabbit anti-CD74 pAb for detection. c:
protein used for coating (300 nM MIF or 500 nM
of other proteins); + : protein tested for binding
to MIF.
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ID: 1MIF) and the membrane-distal trimerisation domain of CD74 (PDB
ID: 1IIE), hence excluding the disordered region N-terminal to the tri-
merisation domain. Our results, especially the lack of interaction of
sssCD74 with MIF in our ELISA assay (Fig. 5C), indicate that the
membrane-distal CD74 trimerisation domain is not or only weakly in-
volved in the interaction with MIF, and is not suﬃcient for a high af-
ﬁnity interaction.
In order to get further insight in the formation of a complex between
MIF and CD74, we performed a dose-dependent ELISA with MBP-sCD74
and Fh8-ssCD74 (Fig. 6). Whereas the binding isotherm of MBP-sCD74
leads to an EC50-value of approximately 110 nM, Fh8-ssCD74 leads to a
2.5-fold higher value of approximately 280 nM, suggesting that removal
of residues 77–112 of CD74 is aﬀecting but not destructing the inter-
action with MIF. Together with the lack of MIF-binding by sssCD74 (i.e.
amino acids 126–232), these results indicate that CD74 amino acids
113–125 are of primary importance for the interaction with MIF, and
that the amino acids N-terminal to this region add to the binding
ability. ITC binding kinetics measurements conﬁrmed that MIF binds to
MBP-sCD74 (Fig. 7). Complex formation is an exothermic reaction with
a reaction enthalpy (ΔH) of -(2.5 ± 0.5).106 cal/mol. This low en-
thalpy value made obtaining solid data of ITC experimentation rather
diﬃcult. The apparent dissociation constant (KD) was 1.3 ± 0.1 μM.
This aﬃnity is lower than the EC50-value obtained with ELISA.
Earlier SPR measurements of the interaction between MIF and
sCD74 have resulted in signiﬁcantly higher reported aﬃnities of 0.23 or
9 nM, depending on the experimental conﬁguration [4]. We note,
however, that the lack of details in this SPR study does not allow a
direct comparison. Interestingly, the same study also shows a sandwich
ELISA that seems to point at an EC50 value in the submicromolar range
of sCD74, which is comparable to our ELISA results. The aﬃnity mea-
surements thus show considerable variety, which may be caused by
diﬀerent complex formation between these multimeric proteins under
diﬀerent experimental conditions. As Leng et al. [4] pointed out: based
on the serum concentration of MIF, one would expect a nanomolar
range aﬃnity for its receptor. In that light it should be noted that the in
vitro results have been obtained with bacterially produced proteins. The
native proteins, with possible post-translational modiﬁcations on MIF
and CD74 (e.g. oxidation and glycosylation; [34]) may have diﬀerent
aﬃnities. In addition, the transmembrane domain of CD74 is also able
to trimerize [35,36] and thus may bring extra stability and raise the
aﬃnity for MIF.
Interestingly, the molar binding ratio in our ITC experiment was
found to be 0.29 ± 0.03. Assuming all MBP-sCD74 and MIF molecules
to be active, this molar ratio indicates that a complex of a trimeric MIF
with 3 trimers of MBP-sCD74 is formed. This suggests that MIF initiates
signaling by clustering the trimeric CD74 receptor into a larger network
that is needed to overcome the threshold for initiation of the signaling
cascade.
4. Conclusions
Our research demonstrated that the luminal portion of CD74 can be
produced at high yields in a bacterial expression system when fused to
the solubility enhancing proteins MBP and Fh8. The puriﬁed fusion
proteins were demonstrated to bind to MIF. The extracellular region
from the transmembrane domain up to the membrane-distal trimer-
isation domain of CD74 appears to be essential for this interaction, with
amino acids 113–125 being an important region, as demonstrated by
the binding assays with diﬀerent constructs.
The successful production of functional CD74 in high quantities,
whether as a fusion protein or as cleaved product, is the ﬁrst step in
further characterisation of its structural features and of the elucidation
of the binding mechanism of mammalian MIF and MIF homologues to
this receptor. Moreover, it will stimulate our search for clinically re-
levant inhibitors of the MIF-CD74 interaction.
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